TGFB1 and Hepatic fibrosis: MSCs engineered with TGF-β also reinforced their therapeutic efficacy for several diseases, such as type 1 diabetes, sepsis and renal ischemia/reperfusion injury, by increasing their immunomodulatory potential, although they rarely had effect on liver fibrosis.